Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen ER for Spasticity in MS
NCT01743651Phase 3Completed
- Sponsor
- RVL Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of arbaclofen in spasticity (3 arms), sponsored by RVL Pharmaceuticals. Primary endpoints: Total Numeric Transformed Modified Ashworth Scale at 120 days and Clinical Global Impression of Change at 120 days. Started Nov 2012; status: completed.
02
Drugs
arbaclofen
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT01743651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743651.